Alaunos Therapeutics (TCRT) Cash from Financing Activities (2009 - 2023)

Alaunos Therapeutics (TCRT) has 15 years of Cash from Financing Activities data on file, last reported at -$12.0 million in Q2 2023.

• Quarterly Cash from Financing Activities changed N/A year-over-year to -$12.0 million in Q2 2023, while the trailing twelve-month figure through Mar 2024 was -$12.0 million (down 5832.06% YoY) and the FY2025 annual result came in at $3.3 million, changed N/A from the prior year.
• Cash from Financing Activities slipped to -$12.0 million in Q2 2023, from -$6.2 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $101.7 million in Q1 2020 to a low of -$12.0 million in Q2 2023.
• A 5-year average of $11.7 million and a median of $230000.0 in 2019 frame the typical range for Cash from Financing Activities.
• The widest YoY moves for Cash from Financing Activities: up 92218.52% in 2021, down 146.5% in 2021.
• Tracing TCRT's Cash from Financing Activities over 5 years: stood at $3.0 million in 2019, then slumped by 86.8% to $400000.0 in 2020, then tumbled by 146.5% to -$186000.0 in 2021, then jumped by 4655.91% to $8.5 million in 2022, then plunged by 241.37% to -$12.0 million in 2023.
• The last three Cash from Financing Activities figures came in at -$12.0 million (Q2 2023), -$6.2 million (Q1 2023), and $8.5 million (Q4 2022), per Business Quant data.